Andrew Mountain

2.5k citations

31 papers · 1.9k indexed · h-index 21

Molecular Biology top 5%
Genetics top 5%
Oncology top 5%
Radiology, Nuclear Medicine and Imaging top 5%
Biotechnology top 2%

Co-authors: S. Baumberg Lawrence S. Young Philip R. Hamann Janis Upeslacis Carl F. Beyer Lois M. Hinman Dan Shochat Ryan E. Holcomb
Topics: Virus-based gene therapy research (12 papers)Cancer Research and Treatments (9 papers)Bacterial Genetics and Biotechnology (5 papers)
Cited by: Biotechnology Genetics Molecular Biology
Journals: Nucleic Acids Research Journal of Biological Chemistry Journal of Clinical Oncology
Partner nations: United Kingdom United States Ireland

In The Last Decade

Andrew Mountain

30 papers receiving 1.8k citations

Peers

Countries citing papers authored by Andrew Mountain

Since Specialization

Citations

This map shows the geographic impact of Andrew Mountain's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew Mountain with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew Mountain more than expected).

Fields of papers citing papers by Andrew Mountain

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew Mountain. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew Mountain. The network helps show where Andrew Mountain may publish in the future.

Co-authorship network of co-authors of Andrew Mountain

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew Mountain. A scholar is included among the top collaborators of Andrew Mountain based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew Mountain. Andrew Mountain is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	CpG-island fragments from the HNRPA2B1/CBX3genomic locus reduce silencing and enhance transgene expression from the hCMV promoter/enhancer in mammalian cells 2005 ·BMC Biotechnology ·Steven G. Williams,(unknown),(unknown),Mark Griffiths,David J. Simpson,Michael Antoniou,Alistair S. Irvine,Andrew Mountain,Robert Crombie	108
2	Antitumor immune responses mediated by adenoviral GDEPT using nitroreductase/CB1954 is enhanced by high-level coexpression of heat shock protein 70 2005 ·Cancer Gene Therapy ·(unknown),Stephen Todryk,Steven Pelech,Christopher J. Wrighton,Alistair S. Irvine,Andrew Mountain,(unknown)	10
3	Nitroreductase-based therapy of prostate cancer, enhanced by raising expression of heat shock protein 70, acts through increased anti-tumour immunity 2005 ·Cancer Immunology Immunotherapy ·(unknown),Steven Pelech,Andrew Mountain,Alistair S. Irvine,Robert Kraaij,Chris H. Bangma,Kingston H. G. Mills,Stephen Todryk	19
4	663: Suicide Gene Therapy Using Adenovirus Encoded Nitroreductase (NTR) and CB1954 in Patients with Localized Prostate Cancer 2005 ·The Journal of Urology ·Prashant Patel,Vivien Mautner,James G. Young,Dan Jackson,Diana Hull,Anjna Badhan,Peter F. Searle,Andrew Mountain,John Ellis,Elizabeth Peers,Alan Doherty,D. M. A. WALLACE,Hing Y. Leung,Lawrence S. Young,Nicholas D. James	1
5	NITROREDUCTASE: A PRODRUG‐ACTIVATING ENZYME FOR CANCER GENE THERAPY 2004 ·Clinical and Experimental Pharmacology and Physiology ·Peter F. Searle,Ming‐Jen Chen,Longqin Hu,Paul R. Race,Andrew L. Lovering,Jane I. Grove,Christopher P. Guise,Mansooreh Jaberipour,Nicholas D. James,Vivien Mautner,Lawrence S. Young,Rachel Kerr,Andrew Mountain,Scott A. White,Eva I. Hyde	107
6	Optimization of a synthetic β-catenin-dependent promoter for tumor-specific cancer gene therapy 2004 ·Molecular Therapy ·(unknown),(unknown),Jonathan M. Gawn,(unknown),Norman J. Maitland,Daniel H. Palmer,Andrew Mountain,Alistair S. Irvine,Christopher J. Wrighton	28
7	Transgenes encompassing dual-promoter CpG islands from the human TBP and HNRPA2B1 loci are resistant to heterochromatin-mediated silencing 2003 ·Genomics ·Michael Antoniou,Lee Harland,(unknown),Steven G. Williams,Jolyon Holdstock,Ernesto Yagüe,(unknown),Mark Griffiths,Sian Edwards,Panayiotis A. Ioannou,Andrew Mountain,Robert Crombie	111
8	High-Level, β-Catenin/TCF-Dependent Transgene Expression in Secondary Colorectal Cancer Tissue 2001 ·Molecular Therapy ·(unknown),(unknown),Tariq Ismail,Andrew Mountain,Lawrence S. Young,Christopher J. Wrighton	23
9	Combined Adenovirus-Mediated Nitroreductase Gene Delivery and CB1954 Treatment: A Well-Tolerated Therapy for Established Solid Tumors 2001 ·Molecular Therapy ·(unknown),Tina Thomson,Hing Y. Leung,Peter F. Searle,Lawrence S. Young,David J. Kerr,Peter A. Harris,Andrew Mountain,Christopher J. Wrighton	45
10	Sensitisation of human carcinoma cells to the prodrug CB1954 by adenovirus vector-mediated expression ofE. coli nitroreductase 2000 ·International Journal of Cancer ·(unknown),Nicola K. Green,Iain A. McNeish,(unknown),Vivien Mautner,Christopher J. Wrighton,Andrew Mountain,Lawrence S. Young,Rachel Kerr,Peter F. Searle	63
11	Expression of Escherichia coli B nitroreductase in established human tumor xenografts in mice results in potent antitumoral and bystander effects upon systemic administration of the prodrug CB1954 2000 ·Cancer Gene Therapy ·(unknown),Alison N. Hulme,M. Dexter,Andrew Mountain,Lawrence S. Young,Peter F. Searle,Rachel Kerr,Christopher J. Wrighton	49
12	Gene therapy: the first decade 2000 ·Trends in biotechnology ·Andrew Mountain	262
13	Efficient nonviral transfection of dendritic cells and their use for in vivo immunization 2000 ·Nature Biotechnology ·Alistair S. Irvine,Peter Trinder,David L. Laughton,(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),Lawrence S. Young,Andrew Mountain	77
14	Conversion of highly malignant colon cancer from an aggressive to a controlled disease by oral administration of a metalloproteinase inhibitor 1997 ·Clinical & Experimental Metastasis ·(unknown),Xiaoen Wang,N. Willmott,Surinder K. Chander,Simon Tickle,Andrew Docherty,Andrew Mountain,Andrew T. Millican,Richard Morphy,John Porter,(unknown),Tetsuro Kubota,A. R. Moossa,(unknown)	48
15	Co‐expression of human protein disulphide isomerase (PDI) can increase the yield of an antibody Fab′ fragment expressed inEscherichia coli 1996 ·FEBS Letters ·David P. Humphreys,Neil Weir,Alastair D. G. Lawson,Andrew Mountain,Peter A. Lund	40
16	An in Vivo Model for Screening Peptidomimetic Inhibitors of Gelatinase A 1995 ·Journal of Pharmaceutical Sciences ·Surinder K. Chander,Pari Antoniw,Nigel R. A. Beeley,Byron A. Boyce,Thomas Crabbe,Andrew Docherty,J. C. Leonard,Barbara Mason,Kenneth Millar,Andrew T. Millican,Richard Morphy,Andrew Mountain,James P. O’Connell,John Porter,N. Willmott	10
17	Human Protein Disulfide Isomerase Functionally Complements a dsbA Mutation and Enhances the Yield of Pectate Lyase C in Escherichia coli 1995 ·Journal of Biological Chemistry ·David P. Humphreys,Neil Weir,Andrew Mountain,Peter A. Lund	47
18	Multimerization behaviour of single chain Fv variants for the tumour-binding antibody B72.3 1994 ·Protein Engineering Design and Selection ·Dominique Desplancq,David J. King,Alastair D. G. Lawson,Andrew Mountain	99
19	Nudeotide sequence of a thermostableβ-galactosidase fromSulfolobus solfataricus 1989 ·Nucleic Acids Research ·Stephen F. Little,(unknown),Catherine E. Campbell,(unknown),(unknown),Andrew Mountain,Martyn K. Robinson	26
20	Cloning of a Bacillus subtilis restriction fragment complementing auxotrophic mutants of eight Escherichia coli genes of arginine biosynthesis 1984 ·Molecular and General Genetics MGG ·Andrew Mountain,Nicholas H. Mann,(unknown),S. Baumberg	41

About Andrew Mountain

Andrew Mountain is a scholar working on Biotechnology, Genetics and Molecular Biology, having authored 31 papers that have together received 1.9k indexed citations. Recurring topics across this work include Virus-based gene therapy research (12 papers), Cancer Research and Treatments (9 papers) and Bacterial Genetics and Biotechnology (5 papers). The work is most often cited by research in Biotechnology (261 citations), Genetics (655 citations) and Molecular Biology (1.3k citations). Andrew Mountain has collaborated with scholars based in United Kingdom, United States and Ireland. Frequent co-authors include S. Baumberg, Lawrence S. Young, Philip R. Hamann, Janis Upeslacis, Carl F. Beyer, Lois M. Hinman, Dan Shochat, Ryan E. Holcomb, Irwin D. Bernstein and Alastair D. G. Lawson. Their work appears in journals such as Nucleic Acids Research, Journal of Biological Chemistry and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact